“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients
EGFR TKIs are not curative, and targeted resistance inevitably results in therapeutic failure. Additionally, there are numerous uncommon EGFR mutations that are insensitive to EGFR TKIs, and there is a lack of clinical strategies to overcome these limitations. EGFR TKI and mAbs target EGFR at differ...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.952939/full |
| _version_ | 1828779901224747008 |
|---|---|
| author | Guoqing Zhang Beibei Yan Yanan Guo Hang Yang Jindong Li |
| author_facet | Guoqing Zhang Beibei Yan Yanan Guo Hang Yang Jindong Li |
| author_sort | Guoqing Zhang |
| collection | DOAJ |
| description | EGFR TKIs are not curative, and targeted resistance inevitably results in therapeutic failure. Additionally, there are numerous uncommon EGFR mutations that are insensitive to EGFR TKIs, and there is a lack of clinical strategies to overcome these limitations. EGFR TKI and mAbs target EGFR at different sites, and a combination regimen for delaying/preventing resistance to targeted therapy or obtaining more intensive inhibition for uncommon mutations at cellular, animal and human levels has been explored. This review critically focuses on a combination strategy for uncommon EGFR mutation-positive NSCLC, and discuss the preclinical data, clinical implications, limitations and future prospects of the combination strategy. |
| first_indexed | 2024-12-11T17:09:59Z |
| format | Article |
| id | doaj.art-55743c314f8049c38fbc24faac6cede1 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T17:09:59Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-55743c314f8049c38fbc24faac6cede12022-12-22T00:57:34ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-07-011210.3389/fonc.2022.952939952939“Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected PatientsGuoqing ZhangBeibei YanYanan GuoHang YangJindong LiEGFR TKIs are not curative, and targeted resistance inevitably results in therapeutic failure. Additionally, there are numerous uncommon EGFR mutations that are insensitive to EGFR TKIs, and there is a lack of clinical strategies to overcome these limitations. EGFR TKI and mAbs target EGFR at different sites, and a combination regimen for delaying/preventing resistance to targeted therapy or obtaining more intensive inhibition for uncommon mutations at cellular, animal and human levels has been explored. This review critically focuses on a combination strategy for uncommon EGFR mutation-positive NSCLC, and discuss the preclinical data, clinical implications, limitations and future prospects of the combination strategy.https://www.frontiersin.org/articles/10.3389/fonc.2022.952939/fullepidermal growth factor receptortyrosine kinase inhibitoruncommon mutationNSCLCdrug resistance |
| spellingShingle | Guoqing Zhang Beibei Yan Yanan Guo Hang Yang Jindong Li “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients Frontiers in Oncology epidermal growth factor receptor tyrosine kinase inhibitor uncommon mutation NSCLC drug resistance |
| title | “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients |
| title_full | “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients |
| title_fullStr | “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients |
| title_full_unstemmed | “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients |
| title_short | “Sandwich” Strategy to Intensify EGFR Blockade by Concurrent Tyrosine Kinase Inhibitor and Monoclonal Antibody Treatment in Highly Selected Patients |
| title_sort | sandwich strategy to intensify egfr blockade by concurrent tyrosine kinase inhibitor and monoclonal antibody treatment in highly selected patients |
| topic | epidermal growth factor receptor tyrosine kinase inhibitor uncommon mutation NSCLC drug resistance |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.952939/full |
| work_keys_str_mv | AT guoqingzhang sandwichstrategytointensifyegfrblockadebyconcurrenttyrosinekinaseinhibitorandmonoclonalantibodytreatmentinhighlyselectedpatients AT beibeiyan sandwichstrategytointensifyegfrblockadebyconcurrenttyrosinekinaseinhibitorandmonoclonalantibodytreatmentinhighlyselectedpatients AT yananguo sandwichstrategytointensifyegfrblockadebyconcurrenttyrosinekinaseinhibitorandmonoclonalantibodytreatmentinhighlyselectedpatients AT hangyang sandwichstrategytointensifyegfrblockadebyconcurrenttyrosinekinaseinhibitorandmonoclonalantibodytreatmentinhighlyselectedpatients AT jindongli sandwichstrategytointensifyegfrblockadebyconcurrenttyrosinekinaseinhibitorandmonoclonalantibodytreatmentinhighlyselectedpatients |